Drug intelligence / Profile preview

CCT-001

Development stage: Preclinical
Lead developer: Centenara Labs

Overview

CCT-001 is a preclinical drug candidate being developed by Centenara Labs (formerly Rejuveron Life Sciences) as part of its Telomere Therapeutics program. The drug is designed to repair and restore shortened telomeres, which are the protective caps at the ends of chromosomes that shorten with cellular division and age. Premature telomere shortening is linked to various genetic and age-related diseases. CCT-001 is specifically being investigated for the treatment of Dyskeratosis Congenita (DC), a rare genetic form of bone marrow failure, and Idiopathic Pulmonary Fibrosis (IPF), a progressive lung disease. The specific molecular modality and mechanism of action have not been publicly disclosed.

Targets

telomeric G4 (Telomeric DNA G-quadruplex)

Beyond the preview

Go deeper on CCT-001.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CCT-001.

Explore the full profile